Navigation Links
Elsevier's PharmaPendium(TM) Adds European Medicines Agency (EMEA) Documents
Date:10/14/2008

NEW YORK, October 14 /PRNewswire-FirstCall/ --

- Site Becomes the Only Source of Consolidated, Searchable Access to Both FDA and EMEA Drug Approval Documents

PharmaPendium ( http://www.info.pharmapendium.com/ ), Elsevier's online resource for authoritative drug safety data, has significantly expanded its content offering with a new release containing the European Medicines Agency's (EMEA) European Public Assessment Reports (EPARs). The addition of this content makes PharmaPendium the only source of consolidated, searchable access to US Food and Drug Administration (FDA) and EMEA drug approval documents on a single site, with a single search.

EMEA is the European agency for the evaluation of medicinal products. This new content offers critical insights into the EMEA regulatory point of view, their reasoning underlying drug approval and the qualifications put on that approval.

"The Pharmaceutical industry is facing increasing pressure to identify drug candidates with the best possible safety, delivery and efficacy profiles as early as possible and PharmaPendium is uniquely positioned to address these challenges," commented Philip MacLaughlin, Senior Product Manager at Elsevier.

The EMEA's EPAR documents cover medicines assessed by the Committee for Medicinal Products for Human Use (CHMP). EPAR documents include efficacy, indication, safety and pharmacokinetics data and mode of action information. The EMEA database on PharmaPendium makes readily accessible approximately 80,000 pages of searchable documents for more than 300 active ingredients approved for the European market - some not approved in the US. It also presents preclinical and clinical toxicity and adverse effects data manually extracted from these documents. General product information documents are also included.

"Providing our users with the European Medicines Agency documents adds another impor
'/>"/>

SOURCE Elsevier
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... -- Metanome, Inc., an industry leader in comprehensive microbiome ... name to Diversigen, Inc.  The name was changed ... source for the myriad of services and expertise ... of the microbiome.  From the wide diversity in ... that are difficult to handle, such as low ...
(Date:4/23/2015)... April 23, 2015 Delpor, Inc. (Delpor), ... that the United States Patent and Trademark Office has ... NANOPORâ„¢ technology. US Pat. No. 8,986,727 was ... drug delivery device for the sustained release ... technology for the sustained (zero-order) release of large and ...
(Date:4/22/2015)... , April 22, 2015   MPIRICA ... today announced $1.6M in Series A financing from ... The funding helps accelerate consumer and employer awareness ... covering surgeries at over 4,800 U.S. hospitals. ... you are probably very concerned about choosing the ...
(Date:4/22/2015)... 2015 Over the last ... witnessed tremendous growth primarily due to growth ... support with increased nanotechnology R&D expenditure and ... , http://www.marketsandmarkets.com/requestCustomization.asp?id=65048077 , In this ... is segmented on the basis of products ...
Breaking Biology Technology:Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 3
... Complete Genomics Inc.,a newly launched, third-generation human genome ... Annual BIO Investor Forum,which will be held in San ... president and chief executive officer of,Complete Genomics, will present ... Room of the Palace Hotel, located at 2 New ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that ... Conference on October 28, 2008 at 2:00 p.m.,Pacific Time ... in La,Jolla, California. Jack Lief, Arena,s President and Chief ... company, including its,clinical development and discovery programs., A ...
... demonstrated that low dose sublingual Intermezzo(R), used at ... significantly shortened time to ... Oct. 22 Transcept,Pharmaceuticals, Inc., a privately-held specialty pharmaceutical ... safety and efficacy of,its lead product candidate, Intermezzo(R) (zolpidem ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 2Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 3Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 2Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 3Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 4Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 5Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 6
(Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... Purdue University researchers are collaborating with Chrysler LLC in ... from a contaminated site in north-central Indiana. The ... a former oil storage facility near Kokomo, Ind., this ... been shown to be capable of absorbing trichloroethylene, or ...
... -- Rice University bioengineer Jennifer West is being recognized ... scientific honors, the O,Donnell Award from The Academy of ... O,Donnell Awards, given for excellence in medical, scientific and ... an inscribed statue. West, a pioneer in the field ...
... Ala. A drug originally used to treat iron ... heal and re-grow injured bones, according to researchers at ... researchers injected the drug deferoxamine (DF), which is designed ... found DF triggered the growth of new blood vessels, ...
Cached Biology News:Fighting pollution the poplar way: Trees to clean up Indiana site 2Fighting pollution the poplar way: Trees to clean up Indiana site 3Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3New treatment boosts bone healing and regrowth 2
... Secondary Detection System is intended for use ... Antibody reagents, which contain rat and goat ... by light microscopy in paraffin-embedded tissues. The ... also be used with other rat or ...
... Lower operational costs. More efficient interfacing ... limited sample volumes. Industry demands for ... using microbore chromatography for routine applications. ... adequately satisfy the need to operate ...
... adaptor for the PDS-1000 He biolistic system enables ... the standard system. It fits into the shocking ... splits the helium shock wave over 7 microcarriers. ... particles over this larger area, the system maximizes ...
... Disruption of the mitochondrial transmembrane potential ... events that occur following induction of ... Kit utilizes a lipophilic cation, termed ... marker. MitoLight is a mitochondrial dye ...
Biology Products: